Tranilast
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 522467

CAS#: 70806-55-2 (free acid)

Description: Tranilast is an analog of a tryptophan metabolite. Initially, tranilast was identified as an anti-allergic agent, and used in the treatment of inflammatory diseases, such as bronchial asthma, atypical dermatitis, allergic conjunctivitis, keloids and hypertrophic scars. Subsequently, the results showed that it could be also effective in the management of a wide range of conditions. The beneficial effects of tranilast have also been seen in a variety of disease states, such as fibrosis, proliferative disorders, cancer, cardiovascular problems, autoimmune disorders, ocular diseases, diabetes and renal diseases.


Chemical Structure

img
Tranilast
CAS# 70806-55-2 (free acid)

Theoretical Analysis

MedKoo Cat#: 522467
Name: Tranilast
CAS#: 70806-55-2 (free acid)
Chemical Formula: C18H17NO5
Exact Mass: 327.11067
Molecular Weight: 327.34
Elemental Analysis: C, 66.05; H, 5.23; N, 4.28; O, 24.44

Price and Availability

Size Price Availability Quantity
100.0mg USD 450.0 2 Weeks
200.0mg USD 750.0 2 Weeks
500.0mg USD 1650.0 2 Weeks
1.0g USD 2450.0 2 Weeks
2.0g USD 3950.0 2 Weeks
5.0g USD 6750.0 2 Weeks
Bulk inquiry

Related CAS #: 53902-12-8   70806-55-2 (free acid)   Tranilast sodium    

Synonym: SB-252218; SB 252218; SB252218; MK-341; MK 341; MK341; Tranilast; trans-Tranilast; brand name: Rizaben; Tranilastum; Tranpro.

IUPAC/Chemical Name: (E)-2-(3-(3,4-dimethoxyphenyl)acrylamido)benzoic acid

InChi Key: NZHGWWWHIYHZNX-CSKARUKUSA-N

InChi Code: InChI=1S/C18H17NO5/c1-23-15-9-7-12(11-16(15)24-2)8-10-17(20)19-14-6-4-3-5-13(14)18(21)22/h3-11H,1-2H3,(H,19,20)(H,21,22)/b10-8+

SMILES Code: COC1=C(C=C(C=C1)/C=C/C(=O)NC2=CC=CC=C2C(=O)O)OC

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 327.34 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Chu HQ, Li J, Huang HP, Hao WD, Duan LP, Wei XT. Protective effects of tranilast on oxazolone-induced rat colitis through a mast cell-dependent pathway. Dig Liver Dis. 2015 Sep 25. pii: S1590-8658(15)00615-5. doi: 10.1016/j.dld.2015.09.002. [Epub ahead of print] PubMed PMID: 26455295.

2: Abdelaziz RR, Elkashef WF, Said E. Tranilast reduces serum IL-6 and IL-13 and protects against thioacetamide-induced acute liver injury and hepatic encephalopathy. Environ Toxicol Pharmacol. 2015 Jul;40(1):259-67. doi: 10.1016/j.etap.2015.06.019. Epub 2015 Jun 22. PubMed PMID: 26164743.

3: Tayyab S, Zaroog MS, Feroz SR, Mohamad SB, Malek SN. Exploring the interaction between the antiallergic drug, tranilast and human serum albumin: Insights from calorimetric, spectroscopic and modeling studies. Int J Pharm. 2015 Aug 1;491(1-2):352-8. doi: 10.1016/j.ijpharm.2015.06.042. Epub 2015 Jun 30. PubMed PMID: 26142245.

4: Kim TI, Lee H, Hong HK, Kim KS, Choi SI, Maeng YS, Kim EK. Inhibitory Effect of Tranilast on Transforming Growth Factor-Beta-Induced Protein in Granular Corneal Dystrophy Type 2 Corneal Fibroblasts. Cornea. 2015 Aug;34(8):950-8. doi: 10.1097/ICO.0000000000000466. PubMed PMID: 26020822.

5: Sato H, Fujimori M, Suzuki H, Kadota K, Shirakawa Y, Onoue S, Tozuka Y. Absorption improvement of tranilast by forming highly soluble nano-size composite structures associated with α-glucosyl rutin via spray drying. Eur J Pharm Biopharm. 2015 May;92:49-55. doi: 10.1016/j.ejpb.2015.02.021. Epub 2015 Feb 26. PubMed PMID: 25725261.

6: Almeida Junior GC, Arakawa L, Santi Neto Dd, Cury PM, Lima Filho AA, Sousa SJ, Alves MR, Azoubel R. Preoperative tranilast as adjunctive therapy to primary pterygium surgery with a 1-year follow-up. Arq Bras Oftalmol. 2015 Jan-Feb;78(1):1-5. doi: 10.5935/0004-2749.20150002. PubMed PMID: 25714528.

7: Darakhshan S, Ghanbari A, Gholami Rad F, Bidmeshki Pour A. Tamoxifen and tranilast show a synergistic effect against breast cancer in vitro. Bratisl Lek Listy. 2015;116(1):69-73. PubMed PMID: 25666966.

8: Suwa S, Kasubata A, Kato M, Iida M, Watanabe K, Miura O, Fukuda T. The tryptophan derivative, tranilast, and conditioned medium with indoleamine 2,3-dioxygenase-expressing cells inhibit the proliferation of lymphoid malignancies. Int J Oncol. 2015 Mar;46(3):1369-76. doi: 10.3892/ijo.2015.2825. Epub 2015 Jan 9. PubMed PMID: 25572287.

9: Park S, Park M, Kim BH, Lee JE, Park HJ, Lee SH, Park CG, Kim MH, Kim R, Kim EH, Heo CY, Choy YB. Acute suppression of TGF-ß with local, sustained release of tranilast against the formation of fibrous capsules around silicone implants. J Control Release. 2015 Feb 28;200:125-37. doi: 10.1016/j.jconrel.2014.12.021. Epub 2014 Dec 18. PubMed PMID: 25528612.

10: Darakhshan S, Pour AB. Tranilast: a review of its therapeutic applications. Pharmacol Res. 2015 Jan;91:15-28. doi: 10.1016/j.phrs.2014.10.009. Epub 2014 Nov 10. Review. PubMed PMID: 25447595.

11: Huang LF, Wen C, Xie G, Chen CY. [Effect of tranilast on myocardial fibrosis in mice with viral myocarditis]. Zhongguo Dang Dai Er Ke Za Zhi. 2014 Nov;16(11):1154-61. Chinese. PubMed PMID: 25406563.

12: Betge S, Kunz C, Figulla H, Jung C. Late onset oral treatment with tranilast following large myocardial infarction has no beneficial effects on cardiac remodeling and mortality in rats. Exp Ther Med. 2014 Dec;8(6):1789-1796. Epub 2014 Oct 6. PubMed PMID: 25371734; PubMed Central PMCID: PMC4218635.

13: Darakhshan S, Bidmeshkipour A, Mansouri K, Saeid HM, Ghanbari A. The Effects of Tamoxifen in Combination with Tranilast on CXCL12-CXCR4 Axis and Invasion in Breast Cancer Cell Lines. Iran J Pharm Res. 2014 Spring;13(2):683-93. PubMed PMID: 25237365; PubMed Central PMCID: PMC4157045.

14: Ohshio Y, Hanaoka J, Kontani K, Teramoto K. Tranilast inhibits the function of cancer-associated fibroblasts responsible for the induction of immune suppressor cell types. Scand J Immunol. 2014 Dec;80(6):408-16. doi: 10.1111/sji.12242. PubMed PMID: 25224016.

15: Hanada M, Tsutsumi K, Arima H, Shinjo R, Sugiura Y, Imagama S, Ishiguro N, Matsuyama Y. Evaluation of the effect of tranilast on rats with spinal cord injury. J Neurol Sci. 2014 Nov 15;346(1-2):209-15. doi: 10.1016/j.jns.2014.08.028. Epub 2014 Aug 28. PubMed PMID: 25194634.

16: Higuchi C, Tomita T, Yoshikawa H. Pachydermodactyly treated with tranilast in a young girl. Case Rep Orthop. 2014;2014:132854. doi: 10.1155/2014/132854. Epub 2014 Aug 6. PubMed PMID: 25165590; PubMed Central PMCID: PMC4140150.

17: Yang L, Shao Y, Han HK. Preparation and in vitro/in vivo characterization of tranilast-AMP clay complex for improving drug dissolution and bioavailability. Arch Pharm Res. 2014 Dec;37(12):1554-9. doi: 10.1007/s12272-014-0458-6. Epub 2014 Aug 15. PubMed PMID: 25119994.

18: Xavier FE, Blanco-Rivero J, Sastre E, Caracuel L, Callejo M, Balfagón G. Tranilast increases vasodilator response to acetylcholine in rat mesenteric resistance arteries through increased EDHF participation. PLoS One. 2014 Jul 3;9(7):e100356. doi: 10.1371/journal.pone.0100356. eCollection 2014. PubMed PMID: 24992476; PubMed Central PMCID: PMC4081117.

19: Islam MS, Protic O, Ciavattini A, Giannubilo SR, Tranquilli AL, Catherino WH, Castellucci M, Ciarmela P. Tranilast, an orally active antiallergic compound, inhibits extracellular matrix production in human uterine leiomyoma and myometrial cells. Fertil Steril. 2014 Aug;102(2):597-606. doi: 10.1016/j.fertnstert.2014.05.013. Epub 2014 Jun 14. PubMed PMID: 24934492.

20: Phan TV, Ke K, Sul OJ, Park YK, Kim KK, Cho YS, Chung HT, Choi HS. Protection against ovariectomy-induced bone loss by tranilast. PLoS One. 2014 Apr 21;9(4):e95585. doi: 10.1371/journal.pone.0095585. eCollection 2014. PubMed PMID: 24751945; PubMed Central PMCID: PMC3994081.

Tranilast

100.0mg / USD 450.0